Company Description
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally.
It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
It sells its products through the company’s web stores, third-party online retailers and distribution partners.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Justin Hall |
Contact Details
Address: 2000 Powell Street, Suite 1150, eleventh floor Emeryville, California 94608 United States | |
| Phone | 510 899 8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P3001 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin M. Hall Esq. | President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 8-K | Current Report |
| Dec 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |